Inclusion Criteria:a) Multiple myeloma which is responsive to therapy. Eligible patients
may have early or relapsed disease. Patients must have Stage II-III disease or have
progression after initial treatment of Stage I disease. Patients who have relapsed
following autologous transplantation may be eligible for this protocol.

b) Age <= 60 years. c) No prior therapy which would preclude the use of low-dose total body
irradiation.

d) Patients must have their pathology reviewed and the diagnosis confirmed at Stanford
University Medical Center. Patients with smoldering multiple myeloma, monoclonal gammopathy
of unknown significance, or amyloidosis will be excluded from this study.

e) Patients must have a Karnofsky performance status > 70%. f) DLCO >= 60% predicted. g)
ALT and AST must be < 2X normal. Total bilirubin less than 2 mg/dl. h) Serum creatinine <
2.0 or 24-hour creatinine clearance >= 50 ml/min. i) Patients must be HIV negative. j)
Pregnant or lactating women will not be eligible to participate. k) Patients must provide
signed, informed consent. Exclusion Criteria:a) Severe psychological or medical illness b)
Patients who have undergone prior allogeneic hematopoietic cell transplantation will not be
eligible for this study.

c) Patients who have an HLA-identical sibling donor will be excluded